Pharma Focus Asia
KP - Choose our fully recyclable blister films

Amdizalisib (HMPL-689) Discovered for the Treatment of Relapsed or Refractory Follicular Lymphoma

Hutchmed Limited discovered novel therapy amdizalisib (HMPL-689), for the treatment of relapsed or refractory follicular lymphoma (“FL”).

Amdizalisib is an inhibitor for PI3Kδ (phosphoinositide 3-kinase delta),a lipid kinase which helps in controlling the activation of several important signaling proteins. Moreover, when antigen is binded to B-cell receptors, PI3Kδ activates through the Lyn and Syk signaling cascade.

Novel Amdizalisib (HMPL-689), is an oral inhibitor targetingthe isoform PI3Kδ. Some of its properties include good oral absorption,signifying low risk of drug accumulation and drug-to-drug interaction, moderate tissue distribution and low clearance in preclinical PK studies.

The abnormal action of B-cell receptor signaling leads to the growth of B-cell type hematological cancers, resulting in 85% of all NHL cases. Hence, PI3Kδ is the promising drug considered for the treatment of hematologic cancers.

In US and Europe regions, Amdizalisib is being evaluated in an ongoing Phase I/Ib studyin patients with relapsed or refractory NHL.

Center for Drug Evaluation of China’s National Medical Products Administration (“NMPA”) grants Breakthrough Therapy Designation (“BTD”) foramdizalisib (HMPL-689)to treat relapsed or refractory follicular lymphoma.

Latest Issue
Get instant
access to our latest e-book
THERMOFISHER SEACertara - Is your drug program on trackMasterControl - Manufacturing demoMasterControl - QMS demoBora Pharmaceuticals - Free WhitepaperThermo Fisher Scientific - Rapid Mycoplasma TestingThermoFisher Scientific - Save costs on your downstream process todayThermo Fisher Scientific - PeptonesMerck - Mobius® products5th Annual Pharma Manufacturing and Automation Convention 2023DUPHAT 202410TH ANNUAL GCC PHARMACY CONGRESS 2023Reuters Events - Pharma Customer Engagement USA 202314th Annual Emirates Cardiac Society Conference 2023The International Hand & Wrist Congress 2023LabAsia 2023Pharma & Patient USA 2023Pharma Customer Engagement Europe 2023
MasterControl - 6 Essential Features in an eQMS